Cite
Re: Oishi et al.: LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (Ophthalmology 2014;121:1151-2).
MLA
Tan, Colin S., et al. “Re: Oishi et Al.: LAPTOP Study: A 24-Month Trial of Verteporfin versus Ranibizumab for Polypoidal Choroidal Vasculopathy (Ophthalmology 2014;121:1151-2).” Ophthalmology, vol. 122, no. 1, Jan. 2015, pp. e5–6. EBSCOhost, https://doi.org/10.1016/j.ophtha.2014.07.005.
APA
Tan, C. S., Ngo, W. K., & Lim, L. W. (2015). Re: Oishi et al.: LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (Ophthalmology 2014;121:1151-2). Ophthalmology, 122(1), e5–e6. https://doi.org/10.1016/j.ophtha.2014.07.005
Chicago
Tan, Colin S., Wei Kiong Ngo, and Louis W. Lim. 2015. “Re: Oishi et Al.: LAPTOP Study: A 24-Month Trial of Verteporfin versus Ranibizumab for Polypoidal Choroidal Vasculopathy (Ophthalmology 2014;121:1151-2).” Ophthalmology 122 (1): e5–6. doi:10.1016/j.ophtha.2014.07.005.